scholarly article | Q13442814 |
P50 | author | Frank Balis | Q38641035 |
Tito Fojo | Q89148742 | ||
P2093 | author name string | Elizabeth Fox | |
Brigitte C Widemann | |||
Anne Goodwin | |||
Wendy Goodspeed | |||
P2860 | cites work | Epothilones: mechanism of action and biologic activity | Q28261744 |
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas | Q28285708 | ||
Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial | Q33328543 | ||
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. | Q33369363 | ||
Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial | Q33499553 | ||
Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. | Q34722347 | ||
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models | Q40366025 | ||
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. | Q40472146 | ||
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. | Q42440513 | ||
Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors | Q44772606 | ||
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. | Q45285635 | ||
A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. | Q46413137 | ||
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer | Q46443846 | ||
The epothilone dilemma. | Q50952412 | ||
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane | Q56786884 | ||
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer | Q58614874 | ||
Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes | Q61624860 | ||
Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties | Q71236147 | ||
Accelerated titration designs for phase I clinical trials in oncology | Q73598986 | ||
Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors | Q80532879 | ||
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy | Q80558321 | ||
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy | Q80558327 | ||
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine | Q80558331 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | pharmacokinetics | Q323936 |
teenager | Q1492760 | ||
phase I clinical trial | Q5452194 | ||
ixabepilone | Q11711607 | ||
P304 | page(s) | 550-556 | |
P577 | publication date | 2008-12-15 | |
P1433 | published in | Journal of Clinical Oncology | Q400292 |
P1476 | title | Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors | |
P478 | volume | 27 |
Q38961012 | A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials |
Q39878337 | Adaptive dose modification for phase I clinical trials. |
Q33520467 | Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data |
Q35958048 | Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment |
Q37048013 | Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency |
Q39555847 | Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. |
Q34915389 | Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group |
Q88993176 | Rethinking medulloblastoma from a targeted therapeutics perspective |
Q54559815 | Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. |
Q39432147 | Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth |
Q42170353 | Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152). |
Q47559320 | Voices of children and adolescents on phase 1 or phase 2 cancer trials: A new trial endpoint? |